Home/Pipeline/HLX-1502

HLX-1502

Neurofibromatosis Type 1

Phase 2Active

Key Facts

Indication
Neurofibromatosis Type 1
Phase
Phase 2
Status
Active
Company

About Healx

Healx is a private, clinical-stage biotech applying a proprietary AI platform to transform drug discovery for rare diseases, an area traditionally neglected due to high costs and low success rates. The company has built a pipeline with programs ranging from preclinical to Phase 2, primarily in rare neurology and oncology, and actively partners with patient groups and academic consortia. By using technology to identify novel drug-disease relationships and repurpose known compounds, Healx aims to run multiple programs in parallel, increasing the speed and probability of delivering treatments to patients.

View full company profile

Other Neurofibromatosis Type 1 Drugs

DrugCompanyPhase
UndisclosedGondolaBioLead Optimization
HLX-0213HealxPreclinical